Summary
Plasma mebendazole levels were analysed retrospectively in patients treated for inoperable infections withEchinococcus multilocularis orgranulosus. In 10 patients receiving mebendazole at 4 dose levels there was no relation between dose and plasma concentration. In 17 patients followed on the same dose for more than 18 months, the plasma levels varied with individual coefficients of variation ranging from 27 to 72%. The data reveal the limitations of single measurements of plasma mebendazole and emphasize the need for repeated monitoring. Coadministration of phenytoin and carbamazepine seemed to lower plasma levels, presumably as a result of enzyme induction. It was not possible appreciably to raise the mebendazole concentrations by inhibition of drug metabolizing enzymes with cimetidine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Braithwaite PA, Roberts MS, Allan RJ, Watson TR (1982) Clinical pharmacokinetics of high dose mebendazole in patients treated for crystic hydatid disease. Eur J Clin Pharmacol 22: 161–169
Bryceson ADM, Cowie AGA, Macleod C, White S, Edwards D, Smyth JD, McManus DP (1982) Experience with mebendazole in the treatment of inoperable hydatid disease in England. Trans Roy Soc Med Hyg 76: 510–518
Dawson M, Allan RJ, Watson TR (1982) The pharmacokinetics and bioavailability of mebendazole in man: A pilot study using 3H-mebendazole. Br J Clin Pharmacol 14: 453–455
Feely J, Wilkinson GR, Wood AJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692–695
Kaojarern S, Feldman M, Richardson CT, Brater DC (1981) Tiotidine and cimetidine — kinetics and dynamics. Clin Pharmacol Ther 29: 198–202
Karlaganis G, Münst GJ, Bircher J (1979) High pressure liquid chromatographic determination of the anthelmintic drug mebendazole in plasma. HRC & CC 2: 141–144
Knodell RG, Holtzman JL, Crankshaw DL, Steele NM (1982) Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology 82: 84–88
Luder PJ, Robotti G, Meister FP, Bircher J (1985) High oral doses of mebendazole interfere with growth of larvalEchinococcus multilocularis lesions. J Hepatol 1: 369–377
Luder PJ, Witassek F, Weigand K, Eckert J, Bircher J (1985) Treatment of cystic ehinococcosis(Echinococcus granulosus) with mebendazole: assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens. Eur J Clin Pharmacol 28: 279–285
Michiels M, Hendriks R, Heykants J (1978) A sensitive radio-immuno-assay for mebendazole (R 17635) and flubendazole (R 17889). Janssen research products information service. Preclinical Research Reports Nos R 17635/11 and R 17889/9
Müller E, Akovbiantz A, Ammann RW, Bircher J, Eckert J, Wissler K, Witassek F, Wüthrich B (1982) Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients. Hepatogastroenterology 29: 236–239
Münst GJ, Karlaganis G, Bircher J (1980) Plasma concentrations of mebendazole during treatment of echinococcosis. Preliminary results. Eur J Clin Pharmacol 17: 375–378
Park BK, Breckenridge AM (1981) Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6: 1–24
Perucca E (1982) Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 7: 57–84
Somogyi A, Gugler R (1982) Drug interactions with cimetidine. Clin Pharmacokinet 7: 23–41
Sonne J, Poulsen HE, Døssing M, Larsen NE, Andreasen PB (1981) Cimetidine clearance and bioavailability in hepatic cirrhosis. Clin Pharmacol Ther 29: 191–197
Speeg KV, Patwardhan RV, Avant GR, Mitchell MC, Schenker S (1982) Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology 82: 89–96
WHO Guidelines for surveillance, prevention and control of echinococcosis/hydatidosis (1984) Eckert J, Gemmell MA, Mathyas Z, Soulsby EJL (eds), VPH/81.28
Witassek F, Burkhardt B, Eckert J, Bircher J (1981) Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man. Eur J Clin Pharmacol 20: 427–433
Witassek F, Allan RJ, Watson TR, Woodtli W, Ammann R, Bircher J (1983) Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis. Eur J Clin Pharmacol 25: 81–84
Witassek F, Bircher J (1983) Chemotherapy of larval echinococcosis with mebendazole: Microsomal liver function and cholestasis as determinants of plasma drug level. Eur J Clin Pharmacol 25: 85–90
Author information
Authors and Affiliations
Additional information
Study performed within the framework of the Swiss Echinococcosis Study Group (Coordinators: A. Akovbiantz, R. Ammann, J. Bircher, and J. Eckert)
Rights and permissions
About this article
Cite this article
Luder, P.J., Siffert, B., Witassek, F. et al. Treatment of hydatid disease with high oral doses of mebendazole. Eur J Clin Pharmacol 31, 443–448 (1986). https://doi.org/10.1007/BF00613522
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613522